SCHEMBL2468465

SCHEMBL2468465

COc1ccc(N2CCN(c3c(C)c(C)c4c(c3C)C(c3cccc(C)c3)C(C)(C)O4)CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 1/20 0.40
DRD4 P21917 2/20 0.39
DPP4 P27487 1/20 0.39
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
GAA P10253 1/20 0.35
MAPT P10636 4/20 0.35
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPK1 P28482 2/20 0.35
RECQL P46063 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DRD2 P14416 1/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470586 0.90 PTGS1 (0.43) ALDH1A1DRD4KMT2AMEN1PTGS1
SCHEMBL2473689 0.89 ALDH1A1 (0.38) ALDH1A1KMT2APTGS1PTGS2GAA
SCHEMBL2472828 0.88 GFER (0.39) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL2473710 0.88 KMT2A (0.40) ALDH1A1DRD4KMT2AMEN1PTGS1
SCHEMBL5348524 0.85 MAPT (0.38) ALDH1A1CYP3A4DRD4KMT2AMEN1
SCHEMBL2472440 0.85 HTR1A (0.40) ALDH1A1CYP3A4CYP2C9DRD4KMT2A
SCHEMBL2472850 0.84 L3MBTL1 (0.39) ALDH1A1CYP3A4CYP2C9KMT2AMEN1
SCHEMBL2471507 0.84 MAPT (0.40) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL5340946 0.84 GFER (0.39) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL2470134 0.83 ALDH1A1 (0.34) ALDH1A1KMT2AMEN1PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1411052-B1 BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP claimed
EP-1411052-B1 BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP disclosed
US-20070149558-A1 Benzo-fused 5-membered heterocyclic compounds, their production and use OHKAWA SHIGENORI 2007-06-28 US disclosed
US-7208495-B2 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-24 US disclosed
US-7208495-B2 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-24 US disclosed
US-20040167171-A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-26 US disclosed
EP-1411052-A1 BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149558-A1 Benzo-fused 5-membered heterocyclic compounds, their production and use CBR1, DBH, PARK7 ALDH1A1 1019/4885CYP3A4 87/4885CYP2C9 75/4885
US-20040167171-A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof CYP8B1, PARK7, OXER1 ALDH1A1 1308/4885CYP3A4 49/4885CYP2C9 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.